Intravesical ALT-803 for BCG-unresponsive Bladder Cancer – A Case Report

Citations of this article
Mendeley users who have this article in their library.


The administration of intravesical chemotherapy or BCG often can prolong the progression-free interval after initial transurethral resection in select bladder cancer (BCa) patients. However, 60% of these patients will recur and up to 30% of patients with recurrent BCa will progress and succumb to their disease over a 15 year period, while another 50% will cystectomy in an attempt to control their disease. Thus better therapeutic strategies are needed for patients who have failed intravesical therapy. In this article, we report the treatment of a 91-year-old man with NMIBC with high-risk features that had failed multiple intravesical therapies.




Huang, J., Schisler, J., Wong, H. C., Rosser, C. J., & Sterbis, J. (2017). Intravesical ALT-803 for BCG-unresponsive Bladder Cancer – A Case Report. Urology Case Reports, 14, 15–17.

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free